

Clinical Policy Advisory Group (CPAG)

CLINICAL POLICIES UPDATED PROCEDURES OF LIMITED CLINICAL VALUE POLICIES

Research evidence shows that some interventions are not clinically effective or only effective when they are performed in specific circumstances. The purpose of the Procedures of Limited Clinical Value (PLCV) policy is to clarify the commissioning intentions of the Clinical Commissioning Group (CCG). The CCG will only fund treatment for clinically effective interventions that are then delivered to the right patients.

In line with the group's principle of adopting NHS Evidence Based Interventions (EBI) policies, where they are felt to be more restrictive than the current Derby & Derbyshire policies, the following have been updated:

Derby and Derbyshire CCG	Key Changes
	No EBI policies were reviewed this month

CLINICAL POLICIES UPDATED SUMMARY OF POLICIES

The following clinical policies were updated:

Clinical Policy	Key Changes
Intrauterine Insemination (IUI) Policy	<p>The intention of this policy is to aid couples who are unable to have regular intercourse to demonstrate infertility. The IUI Policy is not intended a fertility treatment policy.</p> <p>The following statement has been added to provide additional clarity:</p> <ul style="list-style-type: none"> This policy is not intended as a fertility treatment policy. The intention of this policy is to aid couples who are unable to have regular intercourse demonstrate infertility. The NHS treatment pathway for infertility starts once infertility is confirmed. For fertility treatment please see the In Vitro Fertilisation (IVF)/ Intracytoplasmic Sperm Injection (ICSI) within Tertiary Infertility Services Policy.

EAST MIDLANDS AFFILIATED COMMISSIONING COMMITTEE POLICY UPDATES CPAG WEBSITE DEVELOPMENT

The Clinical Policies Website went live from 1st April 2019 and will be regularly updated with new information/policies.

<http://www.derbyshiremedicinesmanagement.nhs.uk/>

GOVERNANCE ARRANGEMENTS, POLICIES AND COMMISSIONING STATEMENTS UPDATED SUMMARY

Policy/Commissioning Statement	Key Changes
CPAG Terms of Reference	<p>Addition of the following:</p> <ul style="list-style-type: none"> Contracting as core members of CPAG Planned Care as core members of CPAG Deputy Chief Finance Officer as a core member of CPAG <p>Clarification on CPAG's stance on the approval of pathways and guidance documents.</p>
Comparison of Mid-Essex CCG Clinical Policies	<p>CPAG has reviewed 113 restrictive clinical policies from the Mid-Essex CCG website to help DDCCG identify:</p> <ul style="list-style-type: none"> Scope within existing Derby and Derbyshire clinical policies to promote evidence based interventions Policies that DDCCG would benefit from adopting due to potential efficiency opportunities <p>CPAG were assured that the DDCCG has a comprehensive portfolio of policies and that any opportunity for further efficiency through policy has been raised with the relevant clinical group.</p>

NICE INTERVENTIONAL PROCEDURES GUIDANCE, DIAGNOSTIC PROCEDURES, MEDICAL TECHNOLOGIES GUIDANCE AND MEDTECH INNOVATION BRIEFINGS (IPGS, DTG, MTGS, MIBS)

The DDCCG do not commission and will not fund any procedure or technology assessed by NICE under their IPG, MTG, DTG and MIB programmes unless:

- the provider has submitted a robust, evidenced based business case to the commissioner and this has been subsequently approved

AND

- the NICE IPG states 'use with standard arrangements for clinical governance, consent and audit'
- OR the NICE MTG states 'the case for adoption within the NHS as described is supported by the evidence'
- OR the NICE DTG makes a recommendation as an option for use
- OR the NICE MIB has evaluated the innovation.

The following NICE programme outputs were considered by the group:

IPG/MTG/DTG/MIB	Description	Outcome
IPG663 (Research only)	Midcarpal hemiarthroplasty for wrist arthritis	Do not commission research IPG's
MTG12 (updated from Jan 2013)	EXOGEN ultrasound bone healing system for long bone fractures with non-union or delayed healing	Require a robust business case in order to be considered
MIB194	superDimension Navigation System to help diagnostic sampling of peripheral lung lesions	Require a robust business case in order to be considered
MIB195	MR-proADM test for use with clinical deterioration scores in cases of suspected infection	Require a robust business case in order to be considered

Our CCG continues to monitor and implement IPGs with our main providers.

NHS ENGLAND INNOVATION AND TECHNOLOGY PAYMENTS (ITP)

The DDCCG have no statutory duty to fund the additional costs associated with the implementation of NHS England's Innovation and Technology Payment innovations by the following:

- NHS England Innovation and Technology Tariff (ITT)
- Innovation and Technology Payment
- Evidence Generation Fund

The provider has submitted robust evidence based business case to the commissioner and this has been subsequently approved.

In line with the CCG's commissioning statements, if the provider intends to continue to use the technology or innovation after the funding for the National Programme has ended, a business should be submitted and approved by the CCG.

There were no NHS England ITP and ITT outputs considered by the group in November.